TTTawfiq Turjman

Tawfiq Turjman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tawfiq Turjman has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Indobufen-based dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and network meta-analysis

    by Aparna Gopinath, Jungwook Heo, Afifa Fatima, Amarsimha Yerrajonna, Hannah George, Riyazuddin Mohd, Tawfiq Turjman, Uchechi Blessing Azuwike, Dany Pierre Clitandre Bien-Aimé, Jean Antoni Sebastien Lefevre, et al.

    Objective: Indobufen has been proposed as an aspirin substitute within dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), but has been compared only with aspirin plus clopidogrel. We aimed to estimate the comparative safety and efficacy of indobufen-based DAPT against contemporary antiplatelet strategies after PCI. Methods: In a systematic review and frequentist random-effects network meta-analysis, we searched PubMed/MEDLINE, Embase, and CENTRAL from inception to May 2026 for randomised controlled trials of adults undergoing PCI with drug-eluting stents that compared antiplatelet strategies mapping onto seven pre-specified nodes, with aspirin plus clopidogrel as the reference. Crude per-arm event counts were extracted in duplicate. The connected primary safety outcome was major bleeding (Bleeding Academic Research Consortium [BARC] type 3/5); efficacy outcomes (myocardial infarction, stent thrombosis, all-cause death, stroke) were analysed per component. Odds ratios (ORs) with 95% confidence intervals (CIs) and P-scores were estimated. Results: Eleven trials enrolling more than 55, 000 patients were included. Indobufen plus clopidogrel did not differ significantly from aspirin plus clopidogrel for major bleeding (OR 1.05, 95% CI 0.62–1.78), myocardial infarction (0.91, 0.29–2.89), stent thrombosis (1.27, 0.34–4.74), or stroke (0.96, 0.27–3.44). In a disconnected direct comparison, indobufen reduced BARC 2–5 bleeding (OR 0.62, 0.45–0.84). The significant between-strategy differences concerned others: aspirin plus ticagrelor showed higher major bleeding (2.07, 1.46–2.94) and clopidogrel monotherapy lower (0.38, 0.22–0.64). Every comparison across clusters depended on a single bridging trial, and no network contained closed loops, precluding assessment of inconsistency. Conclusions: Indobufen-based DAPT was comparable, not superior, to aspirin plus clopidogrel across bleeding and ischaemic outcomes, with no signal of increased ischaemic risk. Because only one randomised trial has directly tested indobufen and all comparisons with ticagrelor-based or monotherapy strategies rest on a single bridging trial, the findings primarily support indobufen as a reasonable aspirin-sparing alternative within clopidogrel-based DAPT. Its relative position against other contemporary bleeding-reduction strategies remains unproven. These results reinforce the need for individualised antiplatelet therapy guided by patient-specific ischaemic and bleeding risk. INPLASY registration number: INPLASY202680037.

  • Indobufen-Based Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

    by Aparna Gopinath, Jungwook Heo, Afifa Fatima, Amarsimha Yerrajonnad, Hannah George, Riyazuddin Mohd, Tawfiq Turjman, Uchechi Blessing Azuwike, Dany Pierre Clitandre Bien-Aimé, Jean Antoni Sebastien Lefevre, et al.

    INPLASY202680037 Indobufen-Based Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis Keywords: indobufen, dual antiplatelet therapy, pe…

  • Bilateral Cingulotomy as a Therapeutic Option for Intractable Cancer Pain: a Systematic Review

    by Saurabh Kataria, Jeremiah Hilkiah Wijaya, Utsav Patel, Made Agus Mahendra Inggas, Sahar Shekoohi, Surbhi Dadwal, Nihar Upadhyay, Tawfiq Turjman, Marie Gadaevi, Azade Ismayilova, et al.

    Purpose of Review Cingulotomy, a stereotactic neurosurgical procedure targeting the anterior cingulate cortex, has been explored for various refractory pain and neuropsychiatric conditions. However, while prior reviews have largely focused on chronic non-cancer pain, there remains a significant knowledge gap regarding its role in managing intractable cancer-related pain. This systematic review therefore aimed to evaluate the efficacy and safety of bilateral cingulotomy as a therapeutic option for cancer-associated pain, addressing a highly underexplored but clinically relevant area of neurosurgical palliation. Recent Findings A total of six studies were included, encompassing 172 patients with intractable or metastatic cancer pain who underwent bilateral cingulotomy. Procedures were performed using radiofrequency (RF) or radiofrequency ablation (RFA)–based lesioning at temperatures of approximately 75–80 °C for 60–80 s. Across studies, pain reduction was observed in 60–80% of patients, with variability in long-term durability of relief. Despite differences in technique, lesion parameters, and assessment scales, cingulotomy consistently demonstrated clinically meaningful pain improvement with a low rate of transient cognitive or behavioral side effects. These findings suggest that RFA-guided cingulotomy provides more precise lesioning and better short-term efficacy compared with earlier mechanical or thermocoagulation methods. Summary Bilateral cingulotomy appears to be a safe and promising neurosurgical intervention for patients with intractable cancer pain refractory to conventional therapies. Nevertheless, variations in lesion temperature, duration, and number across studies contribute to heterogeneity in reported outcomes. Future research should focus on standardizing methodology, incorporating long-term neurocognitive monitoring, and expanding multicenter data to strengthen evidence for its clinical application.


  • Open Access

    The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

    by Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, et al.

    The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies. We aim to consolidate existing evidence related to the safety and efficacy of TMZ as adjuvant therapy to radiotherapy (RT). Various electronic platforms were used to conduct a systematic literature review, including PubMed, Europe PMC, SCOPUS, and clinicaltrials.gov. The approach aimed to identify all pertinent studies published up to July 25, 2024. The search incorporated terms such as “glioblastoma,” “temozolomide,” “monotherapy,” and “adjuvant” alongside relevant Medical Subject Headings (MeSH). The key metrics were overall and progression-free survival, while secondary measures concentrated on treatment-related adverse effects, notably hematological issues like anemia, leukopenia, thrombocytopenia, and neutropenia. The overall effect estimates from the forest plots show significant differences favoring TMZ + RT over RT alone. The HR for overall survival is 0.64 (95% CI: 0.58, 0.71), showing a considerable improvement with TMZ + RT. Progression-free survival shows a HR of 0.51 (95% CI: 0.45, 0.58), also demonstrating a significant benefit for TMZ + RT. Combining TMZ with RT generally leads to better overall and progression-free survival outcomes compared to RT alone. However, the two treatment groups have similar toxicity.


  • A Systematic Review and Meta-Analysis of Stem Cell Therapies for Pain in Diabetic Neuropathy, Osteoarthritis, and Spinal Cord Injuries

    by Saurabh Kataria, Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Kevin Yabut, Muhammad Abubakar Ayub, Pankti Maniyar, Nihar Upadhyay, Beso Davitashvili, Jayshil Patel, et al.

    Purpose of Review The use of stem cell therapy is a rapidly evolving and progressing frontier of science that has been used to treat illnesses such as malignancies, immunodeficiencies, and metabolic syndromes. This review aims to give an overview of the use of stem cell therapy in the treatment of pain caused by diabetic neuropathy, osteoarthritis, and other spinal cord pathologies. Recent Findings Pain is defined as a generalized or localized feeling of distress related to a physical or emotional stimulus and can be caused by a multitude of pathologies. The field of pain management has explored many strategies such as gene therapies, neuromodulation, platelet-rich plasma, and numerous pharmacotherapies. The approach to the delivery of these strategies has varied, with the method of stem cell therapy delivery being the focus of this present investigation. In addition, we combined several different studies to analyze the effects of stem cell therapies and improvement in pain scores quantified by the visual analog scale (VAS). The overall results showed a mean difference of -2.58, suggesting that the stem cell treatment group had a lower VAS score at 6 months compared to the control group. Summary The use of different types of stem cells, such as pluripotent and mesenchymal stem cells, play a critical role in the care of cases suffering from pain. Effective delivery methods are evolving and can transform treatment options in the future, for which large cohort studies are warranted.


  • Open Access

    Correction to: The Role of Platelet Rich Plasma in Vertebrogenic and Discogenic Pain: A Systematic Review and Meta-Analysis

    by Saurabh Kataria, Jeremiah Hilkiah Wijaya, Utsav Patel, Kevin Yabut, Tawfiq Turjman, Muhammad Abubakar Ayub, Nihar Upadhyay, Moinulhaq Makrani, Hisham Turjman, Ahmed Mostafa Abdalla Mohamed, et al.


  • Open Access

    The Role of Platelet Rich Plasma in Vertebrogenic and Discogenic Pain: A Systematic Review and Meta-Analysis

    by Saurabh Kataria, Jeremiah Hilkiah Wijaya, Utsav Patel, Kevin Yabut, Tawfiq Turjman, Muhammad Abubakar Ayub, Nihar Upadhyay, Moinulhaq Makrani, Hisham Turjman, Ahmed Mostafa Abdalla Mohamed, et al.

    Purpose of Review: The present investigation evaluates clinical uses and roles of platelet rich plasma in the management of vetrebrogenic and discogenic mediated pain states. Recent Findings: Back pain is a common and significant condition that affects millions of people around the world. The cause of back pain is often complex and multifactorial, with discogenic and vertebrogenic pain being two subtypes of back pain. Currently, there are numerous methods and modalities in which back pain is managed and treated such as physical therapy, electrical nerve stimulation, pharmacotherapies, and platelet-rich plasma. To conduct this systematic review, the authors used the keywords “platelet-rich plasma”, “vertebrogenic pain”, and “discogenic pain”, on PubMed, EuroPMC, Who ICTRP, and clinicaltrials.gov to better elucidate the role of this treatment method for combating vertebrogenic and discogenic back pain. In recent decades, there has been a rise in popularity of the use of platelet-rich plasma for the treatment of numerous musculoskeletal conditions. Related to high concentration of platelets, growth factors, cytokines, and chemokines, platelet-rich plasma is effective in reducing pain related symptoms and in the treatment of back pain. Summary: Platelet-rich plasma use has evolved and gained popularity for pain related conditions, including vertebrogenic and discogenic back pain. Additional well-designed studies are warranted in the future to better determine best practice strategies to provide future clinicians with a solid foundation of evidence to make advancements with regenerative medical therapies such as platelet-rich plasma.